Antigen News and Research

RSS

AI Models Zero In on Antibody Binding Regions to Improve Drug Target Predictions

Focusing on complementarity-determining regions in antibody models leads to better binding affinity predictions, potentially accelerating treatment discovery.

20 Aug 2026

Mapping Functional Polyprotein Cleavage Sites Solves Post Infection Testing Dilemmas

Current coronavirus diagnostics mainly rely on nucleic acid amplification, antibody detection, or viral antigen detection.

17 Aug 2026

Novel Approach Provides a Flexible Foundation for Measuring Coronavirus Protease Activity

A research team has computationally designed a synthetic peptide that enables modular detection of the enzymatic activity of coronavirus 3C-like protease (3CLPro), an enzyme essential for viral replication and maturation.

13 Aug 2026

Modulating T Cell Exhaustion Offers Novel Therapeutic Pathways in Transplantation

A comprehensive new review examines the complex role of T cell exhaustion in organ transplantation, highlighting how this dysfunctional immune state can both promote graft tolerance and create vulnerabilities to infection and malignancy.

7 Aug 2026

Newly Identified Protein Prevents T Cells From Destroying Cancer Cells

Researchers at Mayo Clinic have identified a protein that cancer cells use to suppress the body's immune response, a finding that could support the development of new treatments to improve the effectiveness of cancer immunotherapies.

5 Aug 2026

Microneedle Patches Turn Skin Into a Window for Immune Bioanalysis

Researchers combined local restimulation of skin-resident memory T cells with hydrogel-coated microneedle patches to recruit and sample rare immune cells. In mouse models, the approach recovered more antigen-specific T cells than a blood sample or punch biopsy, while studies in humans supported short-term tolerability and proof-of-concept cell sampling.

28 Jul 2026

3D Mapping of Tonsil Genetic Structures Unlocks Antibody Optimization

About 2 meters worth of genetic material must fit into the nucleus of each and every one of most of our trillions of cells, coiling and winding to form what looks like a tangled mess.

28 Jul 2026

Deep-Learning Holography Detects Elusive Circulating Tumor Cells in Prostate Cancer

Researchers combined microfluidic enrichment, AI-assisted holography, and fluorescence profiling to identify circulating tumor cell candidates in 13 men with metastatic castration-resistant prostate cancer and 8 healthy donors. The platform found higher median candidate counts in patients, while nearly two-thirds of PSMA-positive candidates lacked EpCAM, suggesting EpCAM-dependent assays could miss some cells.

27 Jul 2026

Evaxion Presents New Preclinical Data for Cytomegalovirus Vaccine Program EVX-V1

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

14 Jul 2026

New ATTACH System Overcomes Key Bottleneck in Personalized Immunotherapy Development

A new platform developed by researchers at The University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells.

9 Jul 2026

Eradicating Lingering Cancer Cells Prevents Relapse in B Cell Leukemia

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

9 Jul 2026

Antibody Drug Conjugate Treatment Destroys Hidden B Cell Leukemia

By using the antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat B-cell acute lymphoblastic leukemia (ALL) patients, researchers at The University of Texas MD Anderson Cancer Center were able to eliminate measurable residual disease (MRD), a crucial step in enhancing long-term survival outcomes.

8 Jul 2026

Study: Genetically Engineered CAR T Cells Suppress the Immune System’s Response to Allergen

Genetically engineered CAR T cells expressing artificial receptor proteins are increasingly used in the clinic to boost the immune system's response against leukemias and other cancers.

7 Jul 2026

Cancer Cells Hijack Macrophage Metabolism to Create an Immunosuppressive Tumor Microenvironment

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment. However, instead of attacking cancer cells, they are typically co-opted to support tumor growth, metastasis, and therapeutic resistance.

2 Jul 2026

Scripps Scientists Find Key Vulnerability in Drug-Resistant Enterococcus Strains

Antibiotic resistance is one of the most urgent threats to global health, linked to an estimated 4.7 million deaths worldwide in 2019 alone.

30 Jun 2026

New Progenitor Cell Platform Offers Scalable Source for Immunotherapy

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages.

22 Jun 2026

AI-Designed Protein Nanocages Pave Way for Advanced Drug Delivery

An international research team led by a Korean scientist has succeeded in designing large-scale protein structures that faithfully replicate the self-assembly principles found in naturally occurring viruses, using artificial intelligence (AI).

18 Jun 2026

Peking University Researchers Map High Dimensional Cellular Networks in Tumors

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

13 Jun 2026

Scientists Identify Microglia Immune State Changes for Novel Alzheimer’s Therapies

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer's disease pathology leads to dementia.

5 Jun 2026

Bispecific Antibodies Target Tumors While Sparing Healthy Tissue

A new generation of bispecific antibodies effectively targets cancer cells, minimizing toxicity and enhancing treatment precision in preclinical studies.

3 Jun 2026